Literature DB >> 3179190

Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission.

G Pizzolo1, L Trentin, F Vinante, C Agostini, R Zambello, M Masciarelli, C Feruglio, F Dazzi, G Todeschini, M Chilosi.   

Abstract

A long term follow-up study has been undertaken in 33 patients with acute non-lymphoblastic leukaemia (ANLL) in order to establish whether a correlation exists between the clinical course and the immunologic pattern of lymphoid subpopulations. Peripheral blood lymphoid cells have been investigated longitudinally (each 1 to 4 months) during complete remission (CR), by morphologic, phenotypic and functional analyses. Particular attention has been paid to the evaluation of the natural killer (NK) cell compartment, by the detection of cells expressing an NK-related phenotype and by NK in vitro assay. Among the patients so far evaluable, 20 relapsed (R) and 10 are long survivors in CR 'off therapy' (LS). The most relevant finding was represented by statistically higher values of NK activity observed in LS vs. R patients (P less than 0.01). The removal of adherent cells before the NK assay, performed to investigate the possible inhibitory effect on NK function played by the macrophage component, abolished this difference, due to a selective increase of NK function in the R group. The longitudinal study revealed that NK activity tended to decrease in individual patients who subsequently relapsed. These data suggest a possible role of NK cells in the relapse control of ANLL, although it cannot be excluded that the low level of NK activity observed in the R group is the result of impending relapse rather than its cause.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3179190      PMCID: PMC2246608          DOI: 10.1038/bjc.1988.221

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults.

Authors:  J P Whitecar; G P Bodey; E J Freireich; K B McCredie; J S Hart
Journal:  Cancer Chemother Rep       Date:  1972-08

2.  Inhibition of murine natural killer cell activity by prostaglandins.

Authors:  M J Brunda; R B Herberman; H T Holden
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

3.  Enhanced in vitro cell-mediated cytotoxicity in chronic hepatitis B virus infection: absence of specificity for virus-expressed antigen on target cell membranes.

Authors:  J L Dienstag; A K Bhan
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

Review 4.  Current concepts in immunology: Regulation of the immune response--inducer and suppressor T-lymphocyte subsets in human beings.

Authors:  E L Reinherz; S F Schlossman
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

5.  Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice.

Authors:  K Kärre; G O Klein; R Kiessling; G Klein; J C Roder
Journal:  Nature       Date:  1980-04-17       Impact factor: 49.962

6.  Association between pre-transplant natural kill and graft-versus-host disease after stem-cell transplantation.

Authors:  C Lopez; D Kirkpatrick; M Sorell; R J O'Reilly; C Ching
Journal:  Lancet       Date:  1979-11-24       Impact factor: 79.321

7.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

8.  Beneficial effects of hepatitis in patients with acute myelogenous leukemia.

Authors:  J C Barton; M E Conrad
Journal:  Ann Intern Med       Date:  1979-02       Impact factor: 25.391

9.  Therapy of leukemia by nonimmune syngeneic spleen cells.

Authors:  M A Cheever; P D Greenberg; A Fefer
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

10.  Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.

Authors:  J K Rees; R G Gray; D Swirsky; F G Hayhoe
Journal:  Lancet       Date:  1986-11-29       Impact factor: 79.321

View more
  12 in total

Review 1.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

2.  Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia.

Authors:  Abhishek A Mangaonkar; Kaaren K Reichard; Moritz Binder; Giacomo Coltro; Terra L Lasho; Ryan M Carr; April Chiu; Vivian Negron; Mehrdad Hefazi; Theodora Anagnostou; Michael M Timm; James W Hiebert; Jose C Villasboas; Wilson I Gonsalves; Naseema Gangat; Mithun Shah; Hassan B Alkhateeb; Aref Al-Kali; Michelle A Elliott; Kebede H Begna; Alexandra P Wolanskyj-Spinner; Mark R Litzow; William J Hogan; Stephen M Ansell; Animesh Pardanani; Ayalew Tefferi; Mrinal M Patnaik
Journal:  Blood Adv       Date:  2020-11-10

Review 3.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

4.  Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML.

Authors:  Nathaniel J Buteyn; Ramasamy Santhanam; Giovanna Merchand-Reyes; Rakesh A Murugesan; Gino M Dettorre; John C Byrd; Anasuya Sarkar; Sumithira Vasu; Bethany L Mundy-Bosse; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Immunol       Date:  2020-02-24       Impact factor: 5.422

5.  Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.

Authors:  M B Vidriales; A Orfao; M C López-Berges; M González; J M Hernandez; J Ciudad; A López; M J Moro; M Martínez; J F San Miguel
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

Review 6.  Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.

Authors:  Mattias Carlsten; Marcus Järås
Journal:  Front Immunol       Date:  2019-10-11       Impact factor: 7.561

Review 7.  Unraveling the Role of Innate Lymphoid Cells in AcuteMyeloid Leukemia.

Authors:  Matthew R Lordo; Steven D Scoville; Akul Goel; Jianhua Yu; Aharon G Freud; Michael A Caligiuri; Bethany L Mundy-Bosse
Journal:  Cancers (Basel)       Date:  2021-01-17       Impact factor: 6.575

8.  Generation of adherent lymphokine activated killer (A-LAK) cells from patients with acute myelogenous leukaemia.

Authors:  P Sedlmayr; H Rabinowich; A Winkelstein; R B Herberman; T L Whiteside
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

9.  Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.

Authors:  F Vaz; M R Silva; J L Ascensao
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

10.  Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.

Authors:  Danlin Yao; Ling Xu; Lian Liu; Xiangbo Zeng; Juan Zhong; Jing Lai; Runhui Zheng; Zhenyi Jin; Shaohua Chen; Xianfeng Zha; Xin Huang; Yuhong Lu
Journal:  Biomed Res Int       Date:  2020-10-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.